Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: The multi-ethnic study of atherosclerosis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 490-499

  Brown, Jenifer ^a   De Boer, Ian H ^c,d   Robinson Cohen, Cassianne ^c   Siscovick, David S ^e   Kestenbaum, Bryan ^c,d   Allison, Matthew ^f,g   Vaidya, Anand ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e NEW YORK ACADEMY OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PARATHYROID HORMONE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHENOTYPE; PREDICTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE; AFRICAN AMERICAN; ASIAN AMERICAN; ATHEROSCLEROSIS; BLOOD; CAUCASIAN; DRUG EFFECTS; ETHNOLOGY; HISPANIC; MIDDLE AGED; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN AMERICANS; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PARATHYROID HORMONE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84922569111     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3949     Document Type: Article

References (51)

1. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006; 98(1): 121-128.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-717.
3. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010; 31: 1237-1247.
4. Carbone LD, Cross JD, Raza SH, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol. 2008; 52: 135-138.
5. Salcuni AS, Palmieri S, Carnevale V, et al. Bone involvement in aldosteronism. J Bone Miner Res. 2012; 27: 2217-2222.
6. van Ballegooijen AJ, Kestenbaum B, Sachs MC, et al. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014; 63(12): 1214-1222.
7. van Ballegooijen AJ, Visser M, Cotch MF, et al. Serumvitamin D and parathyroid hormone in relation to cardiac structure and function: The ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab. 2013; 98(6): 2544-2552.
8. van Ballegooijen AJ, Visser M, Kestenbaum B, et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol. 2013; 111: 418-424.
9. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J.2010;31(13): 1591-1598.
10. van Ballegooijen AJ, Reinders I, Visser M, et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: The Hoorn study. J Clin Endocrinol Metab. 2013; 98: E638-E645.
11. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989; 4(3): 283-291.
12. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008; 93(9): 3462-3470.
13. Rossi GP Hyperparathyroidism, arterial hypertension and aortic stiffness: A possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res. 2011; 34(3): 286-288.
14. Brown JM, Vaidya A. Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Curr Opin Endocrinol Diabetes Obes. 2014; 21(3): 193-201.
15. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014; 63(1): 20-31.
16. Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: A clinically relevant research field. Hypertension. 2014; 63(2): 212-214.
17. Chau K, Holmes D, Melck A, Chan-Yan C. Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma. Am J Hypertens. 2014; hpu102.
18. Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: Cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab.2012; 97: E75-E79.
19. Maniero C, Fassina A, Seccia TM, et al. Mild hyperparathyroidism: A novel surgically correctable feature of primary aldosteronism. J Hypertens. 2012; 30: 390-395.
20. Ceccoli L, Ronconi V, Giovannini L, et al. Bone health and aldosterone excess. Osteoporos Int. 2013; 24(11): 2801-2807.
21. Petramala L, Zinnamosca L, Settevendemmie A, et al. Bone and mineral metabolism in patients with primary aldosteronism. Int J Endocrinol. 2014; 2014: 836529.
22. Brunaud L, Germain A, Zarnegar R, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009; 146(6): 1035-1041.
23. Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab. 1992; 75: 988-992.
24. Brown JM, Williams JS, Luther JM, et al. Human interventions to characterize novel relationships between the renin-angiotensin-al-dosterone system and parathyroid hormone. Hypertension. 2014; 63(2): 273-280.
25. Rifkin DE, Khaki AR, Jenny NS, et al. Association of renin and aldosterone with ethnicity and blood pressure: The multi-ethnic study of atherosclerosis. Am J Hypertens. 2014; 27(6): 801-810.
26. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: Objectives and design. Am J Epidemiol. 2002; 156(9): 871-881.
27. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94(2): 340-350.
28. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007; 71(1): 31-38.
29. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, et al. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013; 310(2): 179-188.
30. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 Suppl 1: S62-S69.
31. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612.
32. Sachs MC, Shoben A, Levin GP, et al. Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: The Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2013; 97(6): 1243-1251.
33. Bosworth C, Sachs MC, Duprez D, et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. Clin Endocrinol (Oxf). 2013; 79(3): 429-436.
34. Cavalier E, Delanaye P, Vranken L, et al. Interpretation of serum PTH concentrations with different kits indialysis patients according to the KDIGO guidelines: Importance of the reference (normal) values. Nephrol Dial Transplant. 2012; 27(5): 1950-1956.
35. Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: A population-based study in older men and women. J Intern Med. 2007; 261(6): 558-565.
36. Mateus-Hamdan L, Beauchet O, Bouvard B, Legrand E, Fantino B, Annweiler C. High parathyroid hormone, but not low vitamin D concentrations, expose elderly inpatients to hypertension. Geriatr Gerontol Int. 2013; 13(3): 783-791.
37. Saleh F, Jorde R, Svartberg J, Sundsfjord J. The relationship between blood pressure and serum parathyroid hormone with special reference to urinary calcium excretion: The Tromsø study. J Endocrinol Invest. 2006; 29(3): 214-220.
38. Zhao G, Ford ES, Li C, Kris-Etherton PM, Etherton TD, Balluz LS. Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J Hypertens. 2010; 28(9): 1821-1828.
39. Fischer E, Hannemann A, Rettig R, et al. A high aldosterone-to-renin ratio is associated with high serum parathyroid hormone concentrations in the general population. J Clin Endocrinol Metab. 2013; jc20133214.
40. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enal-april, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation. 2003; 108: 1831-1838.
41. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, inpatients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321.
42. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-153.
43. Maniero C, Fassina A, Guzzardo V, et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011; 58: 341-346.
44. Rossi GP, Ragazzo F, Seccia TM, et al. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension. 2012; 60: 431-436.
45. Pilz S, Tomaschitz A, März W, Cavalier E, Ritz E. Aldosterone and parathyroid hormone: A complex and clinically relevant relationship. Calcif Tissue Int. 2010; 87(4): 373-374.
46. Koiwa F, Komukai D, Hirose M, et al. Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients. Clin Exp Nephrol. 2012; 16: 130-135.
47. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981; 91(3): 457-465.
48. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999; 82(1): 57-61.
49. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007; 3(9): 486-492.
50. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342(3): 145-153.
51. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. AmJHypertens. 1995; 8: 884-893.